Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
Identifieur interne : 002147 ( Main/Exploration ); précédent : 002146; suivant : 002148Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
Auteurs : Frey [États-Unis] ; Robert A. Koeppe [États-Unis] ; Michael R. Kilbourn [États-Unis] ; Thierry M. Vander Borght [États-Unis] ; Roger L. Albin [États-Unis] ; Sid Gilman [États-Unis] ; David E. Kuhl [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 1996-12.
Abstract
We present development and human application of a method for determining the regional cerebral density of the type 2 vesicular monoamine transporter (VMAT2) using positron emission tomography (PET) and [11C]dihydrotetrabenazine (DTBZ). Previous animal studies indicate striatal VMAT2 density is linearly related to the integrity of substantia nigra dopamine neurons and is not subject to drug‐or lesion‐compensatory regulation. In the present studies, kinetic compartmental modeling was employed to estimate blood‐brain [11C]DTBZ transport (K1,) and VMAT2 binding site density (tissue‐to‐plasma DTBZ distribution volume, DV)from the cerebral and plasma DTBZ time courses her intravenous tracer injection. In controls, we found reductions of putamen DTBZ DV with advancing age, corresponding to losses of 0.77% per year in specific VMAT2 binding. Parkinson's disease (PD) patients had reduction in specific DTBZ DV in the putamen (−61%) and in the caudate nucleus (−43%). There was no overlap of lowest specific putamen DTBZ DV between individual elderly controls and PD patients. The present results indicate the suitability of [11C]DTBZ PET for objective quantification of nigrostriatal integrity, including evaluation of PD progression and its possible therapeutic modification.
Url:
DOI: 10.1002/ana.410400609
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging</title><author><name sortKey="Frey" sort="Frey" uniqKey="Frey" last="Frey">Frey</name></author><author><name sortKey="Koeppe, Robert A" sort="Koeppe, Robert A" uniqKey="Koeppe R" first="Robert A." last="Koeppe">Robert A. Koeppe</name></author><author><name sortKey="Kilbourn, Michael R" sort="Kilbourn, Michael R" uniqKey="Kilbourn M" first="Michael R." last="Kilbourn">Michael R. Kilbourn</name></author><author><name sortKey="Vander Borght, Thierry M" sort="Vander Borght, Thierry M" uniqKey="Vander Borght T" first="Thierry M." last="Vander Borght">Thierry M. Vander Borght</name></author><author><name sortKey="Albin, Roger L" sort="Albin, Roger L" uniqKey="Albin R" first="Roger L." last="Albin">Roger L. Albin</name></author><author><name sortKey="Gilman, Sid" sort="Gilman, Sid" uniqKey="Gilman S" first="Sid" last="Gilman">Sid Gilman</name></author><author><name sortKey="Kuhl, David E" sort="Kuhl, David E" uniqKey="Kuhl D" first="David E." last="Kuhl">David E. Kuhl</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B3721161C2002D3E92CABCA5FFFCBE7B7169225F</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/ana.410400609</idno><idno type="url">https://api.istex.fr/document/B3721161C2002D3E92CABCA5FFFCBE7B7169225F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001C22</idno><idno type="wicri:Area/Main/Curation">001952</idno><idno type="wicri:Area/Main/Exploration">002147</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging</title><author><name sortKey="Frey" sort="Frey" uniqKey="Frey" last="Frey">Frey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Internal Medicine (Division of Nuclear Medicine), University of Michigan, Ann Arbor</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Neurology, University of Michigan, Ann Arbor</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Mental Health Research Institute, University of Michigan, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Koeppe, Robert A" sort="Koeppe, Robert A" uniqKey="Koeppe R" first="Robert A." last="Koeppe">Robert A. Koeppe</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Internal Medicine (Division of Nuclear Medicine), University of Michigan, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Kilbourn, Michael R" sort="Kilbourn, Michael R" uniqKey="Kilbourn M" first="Michael R." last="Kilbourn">Michael R. Kilbourn</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Internal Medicine (Division of Nuclear Medicine), University of Michigan, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Vander Borght, Thierry M" sort="Vander Borght, Thierry M" uniqKey="Vander Borght T" first="Thierry M." last="Vander Borght">Thierry M. Vander Borght</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Internal Medicine (Division of Nuclear Medicine), University of Michigan, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Albin, Roger L" sort="Albin, Roger L" uniqKey="Albin R" first="Roger L." last="Albin">Roger L. Albin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Neurology, University of Michigan, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Gilman, Sid" sort="Gilman, Sid" uniqKey="Gilman S" first="Sid" last="Gilman">Sid Gilman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Neurology, University of Michigan, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Kuhl, David E" sort="Kuhl, David E" uniqKey="Kuhl D" first="David E." last="Kuhl">David E. Kuhl</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Departments of Neurology, University of Michigan, Ann Arbor</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-12">1996-12</date><biblScope unit="volume">40</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="873">873</biblScope><biblScope unit="page" to="884">884</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">B3721161C2002D3E92CABCA5FFFCBE7B7169225F</idno><idno type="DOI">10.1002/ana.410400609</idno><idno type="ArticleID">ANA410400609</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We present development and human application of a method for determining the regional cerebral density of the type 2 vesicular monoamine transporter (VMAT2) using positron emission tomography (PET) and [11C]dihydrotetrabenazine (DTBZ). Previous animal studies indicate striatal VMAT2 density is linearly related to the integrity of substantia nigra dopamine neurons and is not subject to drug‐or lesion‐compensatory regulation. In the present studies, kinetic compartmental modeling was employed to estimate blood‐brain [11C]DTBZ transport (K1,) and VMAT2 binding site density (tissue‐to‐plasma DTBZ distribution volume, DV)from the cerebral and plasma DTBZ time courses her intravenous tracer injection. In controls, we found reductions of putamen DTBZ DV with advancing age, corresponding to losses of 0.77% per year in specific VMAT2 binding. Parkinson's disease (PD) patients had reduction in specific DTBZ DV in the putamen (−61%) and in the caudate nucleus (−43%). There was no overlap of lowest specific putamen DTBZ DV between individual elderly controls and PD patients. The present results indicate the suitability of [11C]DTBZ PET for objective quantification of nigrostriatal integrity, including evaluation of PD progression and its possible therapeutic modification.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Frey" sort="Frey" uniqKey="Frey" last="Frey">Frey</name></region><name sortKey="Albin, Roger L" sort="Albin, Roger L" uniqKey="Albin R" first="Roger L." last="Albin">Roger L. Albin</name><name sortKey="Frey" sort="Frey" uniqKey="Frey" last="Frey">Frey</name><name sortKey="Frey" sort="Frey" uniqKey="Frey" last="Frey">Frey</name><name sortKey="Gilman, Sid" sort="Gilman, Sid" uniqKey="Gilman S" first="Sid" last="Gilman">Sid Gilman</name><name sortKey="Kilbourn, Michael R" sort="Kilbourn, Michael R" uniqKey="Kilbourn M" first="Michael R." last="Kilbourn">Michael R. Kilbourn</name><name sortKey="Koeppe, Robert A" sort="Koeppe, Robert A" uniqKey="Koeppe R" first="Robert A." last="Koeppe">Robert A. Koeppe</name><name sortKey="Kuhl, David E" sort="Kuhl, David E" uniqKey="Kuhl D" first="David E." last="Kuhl">David E. Kuhl</name><name sortKey="Vander Borght, Thierry M" sort="Vander Borght, Thierry M" uniqKey="Vander Borght T" first="Thierry M." last="Vander Borght">Thierry M. Vander Borght</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002147 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002147 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B3721161C2002D3E92CABCA5FFFCBE7B7169225F
|texte= Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
}}
| This area was generated with Dilib version V0.6.23. |  |